title: The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis.
abstract: OBJECTIVE
  To evaluate the role of the discriminant factor in predicting mortality and deciding on treatment in acute alcoholic hepatitis.
  
  
  BACKGROUND
  Current guidelines on the treatment of alcoholic hepatitis restrict the use of corticosteroids to patients with discriminant factor > 32 (severe disease) because of the toxicity of steroids. Less toxic forms of therapy, such as proxyphylline, may have a role in patients with lower discriminant factor, if mortality without therapy is common.
  
  
  METHODS
  We performed a 5-year retrospective analysis comparing the outcomes of patients with mild and severe alcoholic hepatitis. Receiver operator characteristic curves were used to study the accuracy of the discriminant factor to predict short-term mortality.
  
  
  RESULTS
  Among the 41 patients with severe alcoholic hepatitis (discriminant factor > 32) and 48 with mild alcoholic hepatitis, 16 (39%) and 8 (16.7%), respectively, died within 28 days of admission. Only 11 (32%) actually received corticosteroid therapy. The sensitivity and specificity of the discriminant factor in predicting mortality was 66.7% and 61.5%, respectively. A receiver operator characteristic curve of the discriminant factor gave the optimal value for the discriminant factor as 33, with the area under the curve being 0.666 (P = 0.0078; 95% CI = 0.531-0.801).
  
  
  CONCLUSIONS
  Using the value of around 32 maximizes sensitivity and specificity of the discriminant factor in predicting mortality in alcoholic hepatitis. However, there is a high mortality in patients with alcoholic hepatitis and a discriminant factor less than 32. Alternative effective agents should be considered in patients with milder alcoholic hepatitis.
authors.affiliation: Department of Medicine, Division of Gastroenterology, Baylor College of Medicine, Houston, TX 77030-3411, USA.
authors.forename: Ketan
authors.initials: K
authors.lastname: Kulkarni
authors.forename: Thomas
authors.initials: T
authors.lastname: Tran
authors.forename: Miles
authors.initials: M
authors.lastname: Medrano
authors.forename: Boris
authors.initials: B
authors.lastname: Yoffe
authors.forename: Richard
authors.initials: R
authors.lastname: Goodgame
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006519:Hepatitis, Alcoholic / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods; D011379:Prognosis; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones